ArticleJournal of the American College of Radiology : JACR2026
Analysis of Lung Cancer Screening Eligibility Among Patients Diagnosed With Lung Cancer: A Retrospective Cohort Study.
Article in Journal of the American College of Radiology : JACR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeWe evaluated lung cancer screening (LCS) eligibility rate under US Preventive Services Task Force (USPSTF) criteria among patients diagnosed with primary lung cancer and examined LCS utilization before lung cancer diagnosis.
methodsPatients aged 50 to 80 years with a lung cancer diagnosis in 2018-2024 who received care at a tertiary health system in Southern California were included. LCS eligibility was determined using available structured smoking history in the electronic medical record. The primary outcome was LCS eligibility using 2021 USPSTF guidelines. Secondary outcomes included low-dose CT (LDCT) completion among LCS-eligible patients during the 2 years preceding their diagnosis based on USPSTF guideline in effect at diagnosis time, the completeness of electronic medical record structured smoking history, and the associations between sociodemographic characteristics and these outcomes.
resultsIn all, 1,867 patients were included (mean age 67 ± 8 years, 51.6% [962 of 1,866] male, 53.4% [955 of 1,790] White, 2.4% [43 of 1,790] Black, 31.5% [564 of 1,790] Asian). Further, 11.6% (208 of 1,786) were Hispanic. At diagnosis, 46.3% (786 of 1,697) were never smokers, 44.5% (756 of 1,697) were former smokers, and 9.1% (155 of 1,697) were current smokers. LCS eligibility was determined for 1,119 patients, of whom 13.2% (148 of 1,119) met eligibility criteria according to the 2021 USPSTF guidelines. Multivariable analysis showed women (odds ratio [OR] 0.32; 95% confidence interval [CI], 0.21-0.47; P < .001), Asian race (OR 0.35; 95% CI, 0.20-0.62; P < .001), other or mixed race (OR 0.48; 95% CI, 0.24-0.97; P = .04), and Hispanic ethnicity (OR 0.38; 95% CI, 0.17-0.82; P = .01) were less likely to be LCS-eligible. Among the 137 eligible patients, only 13 (9.5%) had received LDCT.
conclusionOur findings emphasize two critical barriers to effective LCS: the limited reach of existing eligibility criteria and inadequate uptake of LDCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.